Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis

Kaymaz, Esin; Özer, Elif; Ünverdǐ, Hatǐce; Hücümenoğlu, Sema

doi:10.4103/ijpm.ijpm_204_16

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoreactivity was calculated using the following semiquantitative scale: 3+, 80‐100% positive epithelial cells with EM; 2+, 40‐80% positive epithelial cells with EM; 1+, 20‐40% positive epithelial cells with EM; and −, no reaction. Like other authors, we report two morphologic types of MUC1 expression: normal (apical/superficial) and aberrant (perinuclear/cytoplasmic/cytoplasm‐membrane). The specificity of staining was assessed using negative controls in which (i) the primary antibody was absent; (ii) the primary antibodies were replaced with 3% bovine serum albumin; and (iii) the primary antibodies were replaced with preimmune mouse serum.…”

Section: Methodssupporting

confidence: 86%

Expression of MUC1 in eosinophilic metaplasia of the prostate

et al. 2019

View full text Add to dashboard Cite

Background: Eosinophilic metaplasia (EM) in the prostate is characterized by the presence of eosinophilic cytoplasmic granules in benign prostatic epithelium. These granules show exocrine-type morphology and positive expression for prostate specific antigen (PSA) and some lysosomal markers. The nature and the full immunohistochemical profile of the granules of EM have not been studied in detail yet. Aim:The aim of the current study is to investigate the expression of epithelial mucins (MUCs) in prostatic epithelium with EM. Methods: Twenty specimens from transurethral resection of the prostate (TURP) were reviewed for the presence of EM and were stained with Periodic acid-Schiff's procedure with diastase digestion (PAS.D) and immunostained with PSA and MUCs: MUC1, MUC2, MUC5AC, and MUC6. Results: The EM-foci of all prostate glands are PAS.D, PSA positive and show constant immunoreactivity for MUC1. The expression of MUC1 is with membranous and cytoplasmic localization: predominantly apical with membranous accentuation in the cases of EM with large eosinophilic granules, and perinuclear in EM with small eosinophilic granules. There is no expression of other MUCs (MUC2, MUC5AC, and MUC6) in prostatic EM. Conclusion:We report for the first time that eosinophilic cytoplasmic granules in prostatic EM are MUC1 positive and can vary in size. Based on our immunohistochemical study we suggest that EM of the prostate is not a form of mucinous metaplasia. The present results enrich the available information about the immunophenotype of EM.We assume that MUC1 might serve as a reliable and constant, although nonspecific, immunohistochemical marker of benign EM-phenotype. K E Y W O R D S eosinophilic metaplasia, MUC1, Paneth cell-like changes, prostate

show abstract

Section: Methodssupporting

confidence: 86%

Expression of MUC1 in eosinophilic metaplasia of the prostate

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As we also demonstrated that high levels of MUC1 expression were confirmed in the tumor surface, especially in Ta/is/1 tumor, MUC1 expression might be informative for the cytological diagnosis and the combination of cytology and MUC1 has a potential to detect more UC cases. In fact, Kaymaz et al reported that MUC1 and p53 expression are useful for the diagnosis of noninvasive papillary urothelial neoplasms in BC tissues 21 . Terauchi et al revealed that intracytoplasmic lumina in urine cytology is important for the diagnosis of high‐grade UC and for predicting a poor prognosis, and it is associated with MUC1 expression 46 .…”

Section: Discussionmentioning

confidence: 99%

“…In fact, Kaymaz et al reported that MUC1 and p53 expression are useful for the diagnosis of noninvasive papillary urothelial neoplasms in BC tissues. 21 Terauchi et al revealed that intracytoplasmic lumina in urine cytology is important for the diagnosis of high-grade UC and for predicting a poor prognosis, and it is associated with MUC1 expression. 46 These findings indicate that MUC1 expression has potential application as a diagnostic immunomarker for UC.…”

Section: Discussionmentioning

confidence: 99%

“…14 MUC1 overexpression has been reported in several malignancies and is associated with poor prognosis. [14][15][16][17] Although MUC1 expression in BC has been investigated by several studies, [18][19][20][21][22] MUC1 expression in UTUC has not yet been investigated in detail, and to our knowledge, there are no studies on the association between MUC1 expression and representative cancer-related molecules in UTUC. Additionally, it is still largely unknown whether MUC1 expression can be applied to urine cytology.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker

Kobayashi

Hayashi

Sentani

et al. 2022

Pathology International

View full text Add to dashboard Cite

Mucin 1 (MUC1) overexpression has been reported in many malignancies and is associated with a poor prognosis. However, the clinicopathological significance of MUC1 in upper tract urothelial carcinoma (UTUC) has not been investigated. We analyzed the expression and distribution of MUC1 in UTUC by immunohistochemistry. In normal urothelium, MUC1 expression was observed on the surface of umbrella cells. Meanwhile, the strong expression of MUC1 was observed in cell membranes and cytoplasm in UTUC tissues, and it was detected in 64 (58%) of a total of 110 UTUC cases. MUC1-positive UTUC cases were associated with nodular/flat morphology, high grade, high T stage, and lymphatic and venous invasion and poor prognosis. Additionally, MUC1 expression was associated with high expression of Ki-67, programmed death-ligand 1 (PD-L1), CD44 variant 9 (CD44v9), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), and p53 in UTUC. Furthermore, immunocytochemistry for MUC1 on urine cytology slides demonstrated that the strong staining of MUC1 was more frequently found in tumor cells than in nonneoplastic cells. The diagnostic accuracy of urine cytology was improved by combining MUC1 immunostaining with cytology. These results suggest that MUC1 may be a prognostic biomarker in UTUC, and MUC1

show abstract

“…Current studies suggest multiple signaling pathways are involved in BC progression ( 3 , 4 ), however, specific mechanisms of BC etiology are still unknown. Due to invasive and costly procedures such as cystoscopy, researchers are exploring potential biomarkers from either urine or peripheral blood ( 5 , 6 ). Consequently, investigation of novel noninvasive biomarkers to enhance the early detection of BC is of great importance.…”

Section: Introductionmentioning

confidence: 99%

Enhanced plasma miR‑26a‑5p promotes the progression of bladder cancer via targeting PTEN

Wang

Chen

2018

Oncol Lett

View full text Add to dashboard Cite

The current study aimed to evaluate the expression and specific role of miR-26a-5p in the progression of bladder cancer (BC). Reverse transcription-quantitative polymerase chain reaction analysis was performed to evaluate the level of miR-26a-5p in BC cancer and healthy controls. The present data showed that plasma miR-26a-5p was significantly increased in BC patients. Furthermore, BC tissues exhibited greater levels of miR-26a-5p compared with adjacent non-neoplastic tissues-26a-5p. Compared with BC patients at Ta-T1 stage, the level of miR-26a-5p was significantly elevated in BC patients ≥T2. BC patients at G3 stage demonstrated a higher plasma miR-26a-5p level compared with those at G1/2 stage. Receiver operating characteristic (ROC) analysis indicated that miR-26a-5p could differentiate BC patients from controls. Additionally, Kaplan-Meier analysis demonstrated that plasma miR-26a-5p negatively correlated with survival of BC patients. Dual luciferase reporter assay indicated that miR-26a-5p significantly suppressed the relative luciferase activity of pmirGLO-PTEN-3′UTR compared with the control. In conclusion, the current study indicated novel data that the levels of plasma miR-26a-5p was significantly increased in BC patients. Furthermore, the present study suggested that determination of plasma miR-26a-5p level could help to distinguish BC patients from healthy controls via targeting PTEN.

show abstract

Evaluation of MUC1 and P53 expressions in noninvasive papillary urothelial neoplasms of bladder, their relationship with tumor grade and role in the differential diagnosis

Abstract: MUC1 and p53 may be helpful immunohistochemical markers for distinguishing PUNLMP from LGPUC and HGPUC, when the histologic signs are not obvious.

Cited by 7 publications

References 0 publications

Expression of MUC1 in eosinophilic metaplasia of the prostate

Expression of MUC1 in eosinophilic metaplasia of the prostate

Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker

Enhanced plasma miR‑26a‑5p promotes the progression of bladder cancer via targeting PTEN

Contact Info

Product

Resources

About